The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: Roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment

Biological Chemistry

Volumn 383, Issue 1, 2002, Pages 21-36

  Wind, Troels ^a   Hansen, Martin ^a   Jensen, Jan K ^a   Andreasen, Peter A ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Cell migration; Endocytosis; Fibrinolysis; Invasion; Proteolysis; Serpin

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; REGULATOR PROTEIN; SERINE PROTEINASE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN;

COMPLEX FORMATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; ANIMAL; CELL ADHESION; CHEMISTRY; ENDOCYTOSIS; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL ADHESION; ENDOCYTOSIS; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, LDL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036005954     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2002.003     Document Type: Review

References (176)

1. A synthetic DNA encoding a modified human urokinase resistant to serum plasminogen activator inhibitor
2. Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1
3. Production of plasminogen activator inhibitor 1 by human adipose tissue: Possible link between visceral fat accumulation and vascular disease
4. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein
5. Diversity in catalytic properties of single-chain and two-chain tissue-type plasminogen activator
6. The urokinase-type plasminogen activator system in cancer metastasis: A review
7. Solvent effects on activity and conformation of plasminogen activator inhibitor-1
8. The plasminogen activation system in tumor growth, invasion, and metastasis
9. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop
10. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus
11. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
12. The plasminogen activator inhibitor PAI-1 controls invivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies
13. Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury
14. The urokinase receptor
15. Molecular evolution of plasminogen activator inhibitor-1 functional stability
16. Blood protein defects associated with thrombosis. Laboratory assessment
17. Importance of the hinge region between α-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies
18. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis
19. Fibrinolysis and thrombosis. Baillieres Best
20. Moving membrane up to the front of migrating cells
21. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction
22. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency
23. The pH dependence of serpin-proteinase complex dissociation reveals a mechanism of complex stabilization involving inactive and active conformational states of the proteinase which are perturbable by calcium
24. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis
25. Physiological consequences of loss of plasminogen activator gene function in mice
26. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice
27. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation
28. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: A gene targeting and gene transfer study in mice
29. Impaired arterial neointima formation in mice with disruption of the plasminogen gene
30. The biostructural pathology of the serpins: Critical function of sheet opening mechanism
31. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin
32. 2-macroglobulin receptor/LDL receptor-related protein (LRP)-dependent internalization of the urokinase receptor
33. Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction
34. Plasminogen activators, tissue degradation, and cancer
35. Familial dementia caused by polymerization of mutant neuroserpin
36. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin)
37. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator
38. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: Release of a kinetic block by a heterologous protein surface loop
39. The PAI-1/vitronectin interaction: Two cats in a bag?
40. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?
41. Type-1 plasminogen-activator inhibitor - Conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility
42. An ester bond linking a fragment of a serine proteinase to its serpin inhibitor
43. A regulatory hydrophobic area in the flexible joint region of plasminogen activator inhibitor-1, defined with fluorescent activity-neutralizing ligands ligand-induced serpin polymerization
44. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism
45. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro
46. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene
47. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice
48. 1-antitrypsin reveals targets for rational drug design to prevent conformational disease
49. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene
50. Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: Conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin
51. The structure of a serpin-protease complex revealed by intramolecular distance measurements using donor-donor energy migration and mapping of interaction sites
52. Conformational studies of plasminogen activator inhibitor type 1 by fluorescence spectroscopy analysis of the reactive centre of inhibitory and substrate forms, and of their respective reactive-centre cleaved forms
53. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: Characterization of a large kindred with a null mutation in the PAI-1 gene
54. Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits
55. The use of fluorescent probes to characterize conformational changes in the interaction between vitronectin and plasminogen activator inhibitor-1
56. Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1
57. Structure-function relationships in serpins: Current concepts and controversies
58. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop
59. Identification of positively charged residues contributing to the stability of plasminogen activator inhibitor 1
60. Characterization of plasminogen activator inhibitor 1 mutants containing the P13 to P10 region of ovalbumin or antithrombin III: Evidence that the P13 residue contributes significantly to the active to substrate transition
61. Receptors of the low density lipoprotein (LDL) receptor family in man. Multiple functions of the large family members via interaction with complex ligands
62. Plasminogen activator inhibitor-1 overexpression in nonproliferative diabetic retinopathy
63. Plasminogen activator inhibitor (PAI)-1 overexpression in retinal microvessels of PAI-1 transgenic mice
64. Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitions to latent and substrate forms
65. The crystal structure of plasminogen activator inhibitor 2 at 2.0 Å resolution: Implications for serpin function
66. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants
67. Molecular analysis of ligand binding to the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein-mediated inhibition of ligand binding
68. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator
69. Thrombin-variable region-1 (VR1): Evidence for the dominant contribution of VR1 of serine proteinases to their interaction with plasminogen activator inhibitor-1
70. 1-antitrypsin for structure and function of serpins
71. Structure of a serpin-protease complex shows inhibition by deformation
72. Role of Lys335 in the metastability and function of inhibitory serpins
73. 1-antitrypsin
74. The plasminogen activator system: Biology and regulation
75. Phylogeny of the serpin superfamily: Implications of patterns of amino acid conservation for structure and function
76. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin
77. Fibrinolysis and risk of coronary artery disease
78. The urokinase receptor is a major vitronectin-binding protein on endothelial cells
79. Effects of serpin binding on the target proteinase: Global stabilization, localized increased structural flexibility, and conserved hydrogen bonding at the active site
80. 2-macroglobulin receptor/low-density-lipoprotein-receptor-related protein
81. Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice
82. Engineering of conformations of plasminogen activator inhibitor-1. A crucial role of β-strand 5A residues in the transition of active form to latent and substrate forms
83. Conformational changes of the reactive-centre loop and β-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1
84. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation
85. The urokinase plasminogen activator receptor in regulation of the actin cytoskeleton and cell motility
86. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombin after vascular injury in mice
87. Extending the capabilities of targeted molecular dynamics: Simulation of a large conformational transition in plasminogen activator inhibitor 1
88. The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into β-sheet A
89. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization
90. Localization of vitronectin binding domain in plasminogen activator inhibitor-1
91. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability
92. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition
93. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates
94. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis
95. Partitioning of serpin-proteinase reactions between stable inhibition and substrate cleavage is regulated by the rate of serpin reactive center loop insertion into β-sheet A
96. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding
97. Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system
98. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes
99. Stability of plasminogen activator inhibitor 1 (PAI-1)
100. 1-antitrypsin
101. 1-Antitrypsin Mmalton (Phe52-deleted) forms loop-sheet polymers in vivo. Evidence for the C sheet mechanism of polymerization
102. Lactational competence and involution of the mouse mammary gland require plasminogen
103. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis
104. Serpin-resistant mutants of human tissue-type plasminogen activator
105. Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor-1
106. Restoration of serine protease-inhibitor interaction by protein engineering
107. 1-antitrypsin deficiency variant, Mnichinan
108. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury
109. Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants
110. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients
111. Biology and biochemistry of proteinases in tumor invasion
112. Functional domains of the very low density lipoprotein receptor: Molecular analysis of ligand binding and acid-dependent ligand dissociation mechanisms
113. 2-macroglobulin-proteinase complexes, plasminogen activator inhibitor type-1-plasminogen activator complexes, and receptor-associated protein cluster of eight complement-type repeats
114. Structural basis of latency in plasminogen activator inhibitor-1
115. Type-1 inhibitor of plasminogen activators. Distinction between latent, activated and reactive centre-cleaved forms with thermal stability and monoclonal antibodies
116. Inter-conversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor
117. PAI-1 stability: The role of histidine residues
118. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and mplications for serpin inactivation
119. Sideroxylonal C, a new inhibitor of human plasminogen activator inhibitor type-1, from the flowers of Eucalyptus albens
120. Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitory properties concomitant with an allosteric up-regulation of its antiadhesive properties
121. 2-macroglobulin receptor/LDL receptor-related protein binds urokinase plasminogen activator inhibitor type-1 complex. Evidence that urokinase receptor-bound complexes
122. 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase protects pro-urokinase against binding to the endocytic receptor
123. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes
124. Localisation of epitopes for monoclonal antibodies to urokinase-type plasminogen activator. Relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme
125. 1-proteinase inhibitor Pittsburgh-trypsin covalent complex
126. Topology of the stable serpin-protease complexes revealed by an autoantibody that fails to react with the monomeric conformers of antithrombin
127. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition
128. Distortion of the active site of chymotrypsin complexed with a serpin
129. 1-antichymotrypsin gene associated with chronic lung disease
130. Role of vitronectin and its receptors in haemostasis and vascular remodeling
131. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis
132. r 40 000 receptor-associated protein
133. Mutant mice with scrambled brains: Understanding the signaling pathways that control cell positioning in the CNS
134. Plasminogen activators and plasminogen activator inhibitors: Biochemical aspects
135. 2-macroglobulin receptor/low-density lipoprotein receptor-related protein and receptor involves basic residues in the inhibitor
136. Impaired wound healing in mice with a disrupted plasminogen gene
137. Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes
138. Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli
139. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy
140. Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency
141. Vitronectin and substitution of a β-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against α-helix F
142. 1-antitrypsin deficiency)
143. 1-antitrypsin-deficient variant with mutation on a predicted conserved residue of the serpin backbone
144. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion
145. A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism
146. Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor matrix degradation to be controlled by PAI-1
147. Melanoma cell migration on vitronectin: Regulation by components of the plasminogen activation system
148. 1-antichymotrypsin as seen by enhanced sensitivity to proteolysis
149. 3 binding to vitronectin
150. Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein
151. Serpin tertiary structure transformation
152. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries
153. Structures of active and latent PAI-1: A possible stabilizing role for chloride ions
154. Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 Å and full insertion of the reactive center loop into beta-sheet A
155. Functional effects of single amino acid substitutions in the region of Phe113 to Asp138 in the plasminogen activator inhibitor 1 molecule
156. The B β-sheet in the PAI-1 molecule plays an important role for its stability
157. Intrinsic fluorescence changes and rapid kinetics of proteinase deformation during serpin inhibition
158. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator
159. Neuronal death in the central nervous system demonstrates a non-fibrin substrate for plasmin
160. Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition
161. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate
162. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1)
163. Selective screening of a large phage display library of plasminogen activator inhibitor-1 mutants to localize interaction sites with either thrombin or the variable region of tissue type plasminogen activator
164. The importance of helix F in plasminogen activator inhibitor-1
165. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin
166. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth
167. Identification of the urokinase receptor as an adhesion receptor for vitronectin
168. 1-antitrypsin
169. The inhibition mechanism of serpins. Evidence that the mobile reactive center loop is cleaved in the native protease-inhibitor complex
170. Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1 Implications for antibody-mediated PAI-1-neutralization and vitronectin-binding
171. The role of plasminogen activator inhibitor-1 as inhibitor of platelet and megakaryoblastic cell adhesion
172. Interfering with the inhibitory mechanism of serpins: Crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide
173. The structure of a Michaelis serpin-protease complex
174. 2-macroglobulin receptor regulates cell surface plasminogen activator activity on human trophoblast cells
175. Vitronectin is not essential for normal mammalian development and fertility
176. Polymerization of plasminogen activator inhibitor-1